Skip to main content
Clinical Trials/JPRN-UMIN000019787
JPRN-UMIN000019787
Not Yet Recruiting
N/A

Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide - Neoadjuvant dose-dense chemotherapy for HER2 negative breast cancer

Dept of breast oncology0 sites50 target enrollmentJanuary 1, 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
HER2 negative primary breast cancer
Sponsor
Dept of breast oncology
Enrollment
50
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 1, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Dept of breast oncology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) HER2 positivity 2\) Previous incident of severe complication 3\) Previous incident of institutional pneumonia 4\) Previous incident of drug allergy 5\) Active status of other cancers 6\) Inflammatory breast cancer 7\) Possible pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials